Advertisement

Antiviral interferon-β treatment in patients with chronic viral cardiomyopathy

  • Heinz-Peter Schultheiss
  • Michel Noutsias
  • Uwe Kühl
Part of the Progress in Inflammation Research book series (PIR)

Abstract

The etiology of “idiopathic” dilated cardiomyopathy (DCM) is due to persistence of viruses in ca. 60% of the patients presenting with DCM. This can be concluded from the high rate of detectable viral genomes in endomyocardial biopsy (EMB) samples in such patients. The pivotal role of interferons (IFN) as a natural defense system against viruses is well documented by experimental data. In an open-label pilot trial, 22 patients with EMB-proven persistence of viral genomes [enterovirus (EV), 15 patients; adenovirus (ADV), 7 patients] were treated with recombinant IFN-β1a. In parallel to the viral elimination proven after 6-month antiviral treatment, left ventricular ejection fraction (LVEF) improved, end-diastolic diameters declined significantly, and an amelioration of heart failure symptoms was evident. In patients with immunohistologically proven intramyocardial inflammation a substantial decrease of infiltrates and cell adhesion molecule expression was noted after IFN treatment. There were no severe side effects. Based on the favorable results of this pilot study, the randomized European-wide multicenter BICC trial (Betaferon®: Interferon-β in Patients With Chronic Viral Cardiomyopathy) for IFN-β1b treatment of patients with EMB-proven persistence of EV, ADV and parvovirus B19 (B19V) was conducted.

Keywords

Left Ventricular Ejection Fraction Dilate Cardiomyopathy Acute Myocarditis Viral Elimination Cardiotropic Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW et al (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10: 933–89CrossRefPubMedGoogle Scholar
  2. 2.
    Taylor DO, Stehlik J, Edwards LB, Aurora P, Christie JD, Dobbels F, Kirk R, Kucheryavaya AY, Rahmel AO, Hertz MI (2009) Registry of the international society for heart and lung transplantation: Twenty-sixth official adult heart transplant report-2009. J Heart Lung Transplant 28: 1007–22CrossRefPubMedGoogle Scholar
  3. 3.
    Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kühl U, Maisch B, McKenna WJ et al (2008) Classification of the cardiomyopathies: A position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29: 270–6CrossRefPubMedGoogle Scholar
  4. 4.
    Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I et al (1996) Report of the 1995 World Health Organization/ International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93: 841–2PubMedGoogle Scholar
  5. 5.
    D’Ambrosio A, Patti G, Manzoli A, Sinagra G, Di Lenarda A, Silvestri F, Di Sciascio G (2001) The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: A review. Heart 85: 499–504CrossRefPubMedGoogle Scholar
  6. 6.
    Bowles NE, Richardson PJ, Olsen EG, Archard LC (1986) Detection of Coxsackie-Bvirus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 1: 1120–3CrossRefPubMedGoogle Scholar
  7. 7.
    Pauschinger M, Bowles NE, Fuentes-Garcia FJ, Pham V, Kühl U, Schwimmbeck PL, Schultheiss HP, Towbin JA (1999) Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation 99: 1348–54PubMedGoogle Scholar
  8. 8.
    Kühl U, Pauschinger M, Bock T, Klingel K, Schwimmbeck CP, Seeberg B, Krautwurm L, Noutsias M, Poller W, Schultheiss HP et al (2003) Parvovirus B19 infection mimicking acute myocardial infarction. Circulation 108: 945–50CrossRefPubMedGoogle Scholar
  9. 9.
    Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP (2005) High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 111: 887–93CrossRefPubMedGoogle Scholar
  10. 10.
    Angelini A, Calzolari V, Calabrese F, Boffa GM, Maddalena F, Chioin R, Thiene G (2000) Myocarditis mimicking acute myocardial infarction: Role of endomyocardial biopsy in the differential diagnosis. Heart 84: 245–50CrossRefPubMedGoogle Scholar
  11. 11.
    Caforio AL, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S, Ramondo A, Carturan E, Iliceto S, Thiene G et al (2007) A prospective study of biopsy-proven myocarditis: Prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 28: 1326–33CrossRefPubMedGoogle Scholar
  12. 12.
    Liu PP, Mason JW (2001) Advances in the understanding of myocarditis. Circulation 104: 1076–82CrossRefPubMedGoogle Scholar
  13. 13.
    McCarthy RE, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, Baughman KL (2000) Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 342: 690–5CrossRefPubMedGoogle Scholar
  14. 14.
    Freeman GL, Colston JT, Zabalgoitia M, Chandrasekar B (1998) Contractile depression and expression of proinflammatory cytokines and iNOS in viral myocarditis. Am J Physiol 274: H249–H258PubMedGoogle Scholar
  15. 15.
    Lowenstein CJ, Hill SL, Lafond Walker A, Wu J, Allen G, Landavere M, Rose NR, Herskowitz A (1996) Nitric oxide inhibits viral replication in murine myocarditis. J Clin Invest 97: 1837–43CrossRefPubMedGoogle Scholar
  16. 16.
    Bachmaier K, Neu N, Pummerer C, Duncan GS, Mak TW, Matsuyama T, Penninger JM (1997) iNOS expression and nitrotyrosine formation in the myocardium in response to inflammation is controlled by the interferon regulatory transcription factor 1. Circulation 96: 585–91PubMedGoogle Scholar
  17. 17.
    Li YY, Feng Y, McTiernan CF, Pei W, Moravec CS, Wang P, Rosenblum W, Kormos RL, Feldman AM (2001) Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 104: 1147–52CrossRefPubMedGoogle Scholar
  18. 18.
    Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL (1992) Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257: 387–9CrossRefPubMedGoogle Scholar
  19. 19.
    Torre Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL (1996) Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93: 704–11PubMedGoogle Scholar
  20. 20.
    Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, LeJemtel TH (1996) Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 28: 964–971CrossRefPubMedGoogle Scholar
  21. 21.
    Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL (1998) Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97: 1382–91PubMedGoogle Scholar
  22. 22.
    Baboonian C, Treasure T (1997) Meta-analysis of the association of enteroviruses with human heart disease. Heart 78: 539–43PubMedGoogle Scholar
  23. 23.
    Why HJ, Meany BT, Richardson PJ, Olsen EG, Bowles NE, Cunningham L, Freeke CA, Archard LC (1994) Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 89: 2582–9PubMedGoogle Scholar
  24. 24.
    Fujioka S, Kitaura Y, Ukimura A, Deguchi H, Kawamura K, Isomura T, Suma H, Shimizu A (2000) Evaluation of viral infection in the myocardium of patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 36: 1920–6CrossRefPubMedGoogle Scholar
  25. 25.
    Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A (2003) Immunosuppressive therapy for active lymphocytic myocarditis: Virological and immunologic profile of responders versus nonresponders. Circulation 107: 857–63CrossRefPubMedGoogle Scholar
  26. 26.
    Kühl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, Schultheiss HP (2005) Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 112: 1965–70CrossRefPubMedGoogle Scholar
  27. 27.
    Wessely R, Henke A, Zell R, Kandolf R, Knowlton KU (1998) Low-level expression of a mutant coxsackieviral cDNA induces a myocytopathic effect in culture: An approach to the study of enteroviral persistence in cardiac myocytes. Circulation 98: 450–7PubMedGoogle Scholar
  28. 28.
    Klingel K, Kandolf R (1993) The role of enterovirus replication in the development of acute and chronic heart muscle disease in different immunocompetent mouse strains. Scand J Infect Dis Suppl 88: 79–85PubMedGoogle Scholar
  29. 29.
    Liu P, Aitken K, Kong Y, Opavsky MA, Martino T, Dawood F, Wen W, Kozieradzki I, bachmaier K, Straus D et al (2000) The tyrosine kinase p56Ick is essential in coxsackievirus B3-mediated heart disease. Nat Med 6: 429–434CrossRefPubMedGoogle Scholar
  30. 30.
    Pauschinger M, Doerner A, Kuehl U, Schwimmbeck PL, Poller W, Kandolf R, Schultheiss HP (1999) Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation 99: 889–95PubMedGoogle Scholar
  31. 31.
    Badorff C, Noutsias M, Kühl U, Schultheiss HP (1997) Cell-mediated cytotoxicity in hearts with dilated cardiomyopathy: Correlation with interstitial fibrosis and foci of activated T lymphocytes. J Am Coll Cardiol 29: 429–34CrossRefPubMedGoogle Scholar
  32. 32.
    Schulze K, Witzenbichler B, Christmann C, Schultheiss HP (1999) Disturbance of myocardial energy metabolism in experimental virus myocarditis by antibodies against the adenine nucleotide translocator. Cardiovasc Res 44: 91–100CrossRefPubMedGoogle Scholar
  33. 33.
    Doerner A, Pauschinger M, Schwimmbeck PL, Kuhl U, Schultheiss HP (2000) The shift in the myocardial adenine nucleotide translocator isoform expression pattern is associated with an enteroviral infection in the absence of an active T-cell dependent immune response in human inflammatory heart disease. J Am Coll Cardiol 35: 1778–84CrossRefGoogle Scholar
  34. 34.
    Heymans S, Pauschinger M, De Palma A, Kallwellis-Opara A, Rutschow S, Swinnen M, Vanhoutte D, Gao F, Torpai R, Baker AH et al (2006) Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation 114: 565–73CrossRefPubMedGoogle Scholar
  35. 35.
    Heim A, Stille-Siegener M, Kandolf R, Kreuzer H, Figulla HR (1994) Enterovirusinduced myocarditis: Hemodynamic deterioration with immunosuppressive therapy and successful application of interferon-alpha. Clin Cardiol 17: 563–5CrossRefPubMedGoogle Scholar
  36. 36.
    Matsumori A, Tomioka N, Kawai C (1989) Viral myocarditis: Immunopathogenesis and the effect of immunosuppressive treatment in a murine model. Jpn Circ J 53: 58–60PubMedGoogle Scholar
  37. 37.
    Alsharifi M, Mullbacher A, Regner M (2008) Interferon type I responses in primary and secondary infections. Immunol Cell Biol 86: 239–45CrossRefPubMedGoogle Scholar
  38. 38.
    Manns MP, Wedemeyer H, Cornberg M (2006) Treating viral hepatitis C: Efficacy, side effects, and complications. Gut 55: 1350–9CrossRefPubMedGoogle Scholar
  39. 39.
    Baron S (1992) Introduction to the Interferon System. In: Baron S (ed): Interferon: Principles and Medical Applications. Galveston, TX: The University of Texas Medical Branch at Galveston, Dept. of Microbiology: 1–15Google Scholar
  40. 40.
    Stille-Siegener M, Heim A, Figulla HR (1995) Subclassification of dilated cardiomyopathy and interferon treatment. Eur Heart J 16 Suppl O: 147–9PubMedGoogle Scholar
  41. 41.
    Miric M, Vasiljevic J, Bojic M, Popovic Z, Keserovic N, Pesic M (1996) Long-term follow up of patients with dilated heart muscle disease treated with human leucocytic interferon alpha or thymic hormones initial results. Heart 75: 596–601CrossRefPubMedGoogle Scholar
  42. 42.
    Heim A, Canu A, Kirschner P, Simon T, Mall G, Hofschneider PH, Kandolf R (1992) Synergistic interaction of interferon-beta and interferon-gamma in coxsackievirus B3-infected carrier cultures of human myocardial fibroblasts. J Infect Dis 166: 958–65PubMedGoogle Scholar
  43. 43.
    Deonarain R, Cerullo D, Fuse K, Liu PP, Fish EN (2004) Protective role for interferonbeta in coxsackievirus B3 infection. Circulation 110: 3540–3CrossRefPubMedGoogle Scholar
  44. 44.
    Kuhl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, Poller W, Schultheiss HP (2003) Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107: 2793–8CrossRefPubMedGoogle Scholar
  45. 45.
    Kühl U, Noutsias M, Seeberg B, Schultheiss HP (1996) Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy. Heart 75: 295–300CrossRefPubMedGoogle Scholar
  46. 46.
    Daliento L, Calabrese F, Tona F, Caforio AL, Tarsia G, Angelini A, Thiene G (2003) Successful treatment of enterovirus-induced myocarditis with interferon-alpha. J Heart Lung Transplant 22: 214–7CrossRefPubMedGoogle Scholar
  47. 47.
    Coletta AP, Clark AL, Cleland JG (2009) Clinical trials update from the Heart Failure Society of America and the American Heart Association meetings in 2008: SADHARTCHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, ta-interferon study, BACH, and ATHENA. Eur J Heart Fail 11: 214–9Google Scholar
  48. 48.
    Kühl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, Poller W, Schultheiss HP (2003) Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107: 2793–8CrossRefPubMedGoogle Scholar
  49. 49.
    Modrow S (2006) Parvovirus B19: The causative agent of dilated cardiomyopathy or a harmless passenger of the human myocard? Ernst Schering Res Found Workshop 63–82Google Scholar
  50. 50.
    Streitz M, Noutsias M, Volkmer R, Rohde M, Brestrich G, Block A, Klippert K, Kotsch K, Ay B, Hummel M et al (2008) NS1 specific CD8+ T-cells with effector function and TRBV11 dominance in a patient with parvovirus B19 associated inflammatory cardiomyopathy. PLoS ONE 3: e2361CrossRefPubMedGoogle Scholar
  51. 51.
    Lindner J, Noutsias M, Lassner D, Wenzel J, Schultheiss HP, Kuehl U, Modrow S (2009) Adaptive immune responses against parvovirus B19 in patients with myocardial disease. J Clin Virol 44: 27–32CrossRefPubMedGoogle Scholar
  52. 52.
    Kühl U, Lassner D, Pauschinger M, Gross UM, Seeberg B, Noutsias M, Poller W, Schultheiss HP (2008) Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. J Med Virol 80: 1243–1251CrossRefPubMedGoogle Scholar
  53. 53.
    Pauschinger M, Doerner A, Kühl U, Schwimmbeck PL, Poller W, Kandolf R, Schultheiss HP (1999) Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation 99: 889–95PubMedGoogle Scholar

Copyright information

© Springer Basel 2010

Authors and Affiliations

  • Heinz-Peter Schultheiss
    • 1
  • Michel Noutsias
    • 2
  • Uwe Kühl
    • 1
  1. 1.Department of Cardiology and PneumonologyCharité — Universitätsmedizin BerlinBerlinGermany
  2. 2.Department of Internal Medicine — CardiologyUniversity Hospital of Marburg and Giessen, Philipps-Universität MarburgMarburgGermany

Personalised recommendations